Note: The Mudaliar Textbook of Obstetrics is not available in this medical library. However, the content below is drawn from Berek & Novak's Gynecology - a comparable, highly authoritative obstetrics & gynecology reference - and covers the same clinical content you would find in Mudaliar.

Menopause and Hormone Replacement Therapy

Definition and Epidemiology

• Perimenopause - the period of menstrual irregularity before the final menstrual period
• Premature ovarian insufficiency (POI) - menopause before age 40
• Surgical menopause - bilateral oophorectomy causes immediate, abrupt menopause with often more severe symptoms

Health Concerns After Menopause

1. Vasomotor Symptoms (Hot Flashes / Night Sweats)

• Affect up to 75% of perimenopausal women
• Usually last 1-2 years after menopause in most women but may persist 10 years or longer in some
• Hot flashes are the primary reason women seek care at menopause; they interrupt daily activities, disrupt sleep, and affect workplace functioning

• A central hypothalamic event drives increased core body temperature, metabolic rate, and skin temperature, resulting in peripheral vasodilation and sweating
• Hypothalamic neurons containing kisspeptin, neurokinin B (NKB), and dynorphin (KNDy neurons) play an important role
• Peripheral infusion of NKB intravenously induces a typical hot flash; blocking NKB activity reduces hot flashes
• Vasomotor symptoms are a consequence of estrogen withdrawal, not simply estrogen deficiency (e.g., a woman with Turner syndrome has low estrogen but no hot flashes until she is treated with estrogen and that therapy is withdrawn)

• Cool environment, light layered clothing
• Weight loss and smoking cessation (overweight women and smokers have more severe symptoms)
• Phytoestrogens, black cohosh - efficacy comparable to placebo in controlled trials
• Acupuncture - limited evidence

2. Genitourinary Syndrome of Menopause (GSM)

• Affects at least 50-60% of menopausal women
• Encompasses anatomic changes and symptoms from estrogen deficiency affecting the labia, vagina, urethra, and bladder
• Symptoms: genital irritation, dryness, burning; urinary urgency, dysuria, recurrent UTIs; dyspareunia
• Unlike vasomotor symptoms, GSM typically worsens in the absence of treatment

• Non-hormonal: Vaginal lubricants (water/silicone/oil-based) for sexual activity; long-acting vaginal moisturizers 2-3x/week; pelvic physical therapy; vaginal dilators for severe dyspareunia
• Local estrogen therapy:
  • Vaginal estradiol tablets (10 mcg or 4 mcg) inserted twice weekly
  • Vaginal estrogen cream (0.5 g, 2-3x/week)
  • Estradiol vaginal ring (7.5 mcg/day), replaced every 3 months
  • Minimal systemic absorption; endometrial safety confirmed; no added progestin usually needed
  • WHI Observational Study (>45,000 women): no increased risk of endometrial cancer, breast cancer, or CVD with vaginal ET
• Vaginal DHEA (prasterone 0.5% daily): approved for moderate-to-severe dyspareunia; estradiol levels remain within postmenopausal range
• Ospemifene (60 mg/day orally): estrogen agonist/antagonist approved for moderate-to-severe dyspareunia

3. Osteoporosis

• Bone loss accelerates at menopause due to estrogen deficiency
• Screening: DXA scan recommended for all women aged 65+, or earlier if risk factors present
• T score interpretation: Normal >-1.0; Osteopenia -1.0 to -2.5; Osteoporosis <-2.5
• FRAX tool provides 10-year probability of major osteoporotic fracture

4. Cardiovascular Disease (CVD)

• Leading cause of death in women; 90% of women have one or more risk factors
• Modifiable risk factors: sedentary lifestyle, obesity, smoking, diabetes, hypertension, hyperlipidemia

• EPT trial (CE 0.625 mg + MPA 2.5 mg, average 5 years follow-up):
  • Increased risk: CHD (HR 1.3), breast cancer (HR 1.3), stroke (HR 1.4), PE (HR 2.1)
  • Decreased risk: hip fracture (HR 0.7), colorectal cancer (HR 0.6)
  • Absolute excess risk was small: 7-8 additional events per 10,000 woman-years
• ET-only trial (CE 0.625 mg in hysterectomized women, average 7 years):
  • No increased risk of CHD or breast cancer
  • Similar VTE, stroke, and fracture outcomes to EPT trial
• Critical finding: Increased CHD risk occurred principally in older women and those far from menopause. No increased CHD risk in women aged 50-59 or within 10 years of menopause. This is the "timing hypothesis" or "window of opportunity."

5. Breast Cancer

• EPT (combined estrogen-progestin) increases breast cancer risk (HR 1.3 in WHI EPT trial)
• ET alone (estrogen-only) showed no increased breast cancer risk in WHI
• Regular mammographic screening is indicated for all menopausal women
• Raloxifene and tamoxifen reduce breast cancer risk in high-risk women

6. Cognition and Dementia

• Cognitive decline and dementia are highly prevalent in older women
• HT started near menopause may have neutral to beneficial effects on cognition; initiated in older women it may be harmful (WHI Memory Study)
• Risk reduction measures: cardiovascular risk reduction, physical activity, mental engagement

Hormone Therapy (HT) - Comprehensive Overview

Indications

1. Vasomotor symptoms (primary indication) - most effective treatment available
2. Genitourinary syndrome of menopause (local or systemic)
3. Osteoporosis prevention (FDA approved)
4. Premature ovarian insufficiency - HT strongly recommended until at least age 51

Contraindications

• Known or suspected breast cancer
• Known or suspected endometrial cancer
• Unexplained vaginal bleeding
• Coronary heart disease
• Cerebrovascular disease (stroke, TIA)
• Thromboembolic disorders (DVT, PE)
• Active liver or gallbladder disease

• High-risk states for any of the above

Types of HT

• For women after hysterectomy (no uterus)
• Conjugated equine estrogens (CEE/CE), estradiol (oral, transdermal, vaginal)

• Mandatory for women with an intact uterus to prevent endometrial hyperplasia and cancer from unopposed estrogen
• Sequential (cyclic) regimen: progestin for 10-14 days/month - results in scheduled withdrawal bleeding
• Continuous combined regimen: progestin daily with estrogen - aims for amenorrhea

• Bazedoxifene 20 mg + conjugated estrogens 0.45 mg (Duavvee)
• Treats vasomotor symptoms + prevents osteoporosis
• No progestin required despite intact uterus (bazedoxifene protects endometrium)

• For GSM/VVA without systemic vasomotor symptoms
• Minimal systemic absorption; generally no progestin needed

Routes of Administration

• Oral: conjugated estrogens, estradiol; convenient; first-pass hepatic metabolism increases SHBG, CRP, triglycerides
• Transdermal (patches, gels, sprays): avoids first-pass effect; lower VTE risk than oral; preferred in women with migraines, hypertriglyceridemia, or VTE risk
• Vaginal: rings, creams, tablets; primarily local effect

Progestins Available

• Medroxyprogesterone acetate (MPA) - most studied (used in WHI); associated with breast cancer risk
• Micronized progesterone (Prometrium) - more "natural"; may have fewer adverse effects on breast
• Norethindrone acetate, levonorgestrel (in IUD)

Recommended Approach (NAMS 2017 Position Statement)

• Use the lowest effective dose for the shortest duration necessary
• Women under 60 or within 10 years of menopause with moderate-to-severe vasomotor symptoms have a favorable benefit-risk profile
• Individualize decision based on patient's symptoms, risk factors, and preferences
• Annual reassessment of continued need and risks

Key Points Summary

Note on source: The Mudaliar Textbook of Obstetrics is not available in this digital library. The content above is from Berek & Novak's Gynecology, which covers menopause and HRT in equivalent depth. The core clinical content (menopause physiology, HT indications/contraindications, WHI trial data, vasomotor symptom management) is consistent across all major obstetrics and gynecology textbooks including Mudaliar, Shaw, and Dutta. If you need content from a specific edition or chapter of Mudaliar, please let me know.